Saturday 17 October 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%

Follow VRTX

Alert me

Market cap: $129.0B
P/E: 28.8×
Fwd P/E: 25.5×
Dividend yield: —
F-score: 8/9
Altman Z: 12.06
Beneish M: −2.17
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 158.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	4	2	24	5	1	6	5	3	—	—	—

Insider Ownership 0.32%

Capital & Financial Ratios $m

Market Cap 128,950.00

Revenue 12,587.20

Net Income 4,405.20

Free Cash Flow 3,796.10

Net Debt (7,852.40)

Current Ratio 3.19

Debt/Equity 0.00

P/E ratio 28.82

Fwd P/E 25.50

P/S ratio 10.07

P/B ratio 6.26

Past 5Y EPS Growth 8.29%

This Y EPS Growth 1.52%

Next Y EPS Growth 12.69%

Next Y revenue growth 10.45%

Next 5Y EPS Growth 10.99%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 57.09%

10-year low 10-year high

P/S against its own 10 years 38.52%

10-year low 10-year high

P/B against its own 10 years 31.29%

10-year low 10-year high

EV/Sales against its own 10 years 39.11%

10-year low 10-year high

EV/FCF against its own 10 years 54.53%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11,218	6,116	6,608	7,852
Receivables	1,563	1,609	2,053	2,134
Inventory	739	1,205	1,687	1,765
Other	—	—	—	—
	14,144	9,596	11,201	12,544

	2023	2024	2025	Q'26
Payables	365	413	462	430
ST’ Debt	—	—	—	—
Other	527	363	428	329
	3,547	3,565	3,861	3,938

Compound Annual Growth %

	10y	5y	3y
Sales	27.80%	14.10%	10.35%
Cash Flow	0.00%	2.22%	(4.20%)
Earnings	0.00%	7.83%	5.97%
Book Value	32.81%	16.53%	10.29%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2,987	3,334	—	—	—
’25	2,770	2,965	3,076	3,190	12,001
’24	2,691	2,646	2,772	2,912	11,020
’23	2,375	2,493	2,484	2,518	9,869
’22	2,098	2,196	2,334	2,303	8,931
’21	1,724	1,793	1,984	2,073	7,574
’20	1,515	1,524	1,538	1,628	6,206

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,428	1,125	—	—	—
’25	819	1,073	1,241	498	3,631
’24	1,307	(3,754)	1,370	585	(493)
’23	900	1,134	1,268	235	3,537
’22	956	1,140	956	1,078	4,130
’21	921	(200)	927	995	2,644
’20	816	1,039	908	492	3,254

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,295	1,013	—	—	—
’25	778	927	1,140	349	3,194
’24	1,058	(3,830)	1,302	492	(978)
’23	858	1,075	1,228	119	3,279
’22	893	1,087	901	1,045	3,925
’21	850	(250)	875	933	2,409
’20	796	1,021	733	444	2,994

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	4.02	4.31	—	—	—
’25	2.49	3.99	4.20	4.65	15.32
’24	4.21	(13.92)	4.01	3.50	(2.08)
’23	2.69	3.52	3.97	3.71	13.89
’22	2.96	3.13	3.59	3.15	12.82
’21	2.49	0.26	3.28	3.00	9.01
’20	2.29	3.18	2.53	2.30	10.29

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	71.46	73.34	144.07	160.95	197.47	176.36	214.66	282.21	377.85	362.50	Analyst estimates 2026–2028 Powerpack
	High	124.96	167.86	194.92	225.66	306.08	242.99	324.75	413.00	519.88	519.68
People
People	Employees	2,150	2,300	2,500	3,000	3,400	3,900	4,800	5,400	6,100	6,400
	Revenue/emp, $m	0.79	1.08	1.22	1.39	1.83	1.94	1.86	1.83	1.81	1.88
Income, $m
Income, $m	Revenue	1,702	2,489	3,048	4,163	6,206	7,574	8,931	9,869	11,020	12,001
	Gross margin, %	87.64	88.95	86.56	86.84	88.14	88.06	87.90	87.21	86.11	86.24
	EBT	(67)	(16)	600	1,395	3,117	2,730	4,232	4,380	249	4,643
	EBT margin, %	(3.96)	(0.63)	19.70	33.51	50.23	36.05	47.39	44.38	2.25	38.69
	Net income	(84)	92	2,087	1,177	2,712	2,342	3,322	3,620	(536)	3,953
	Depreciation	61	61	72	107	110	126	148	181	207	210
Per share, $
Per share, $	Revenue	6.96	10.00	11.98	16.22	23.89	29.39	34.87	38.30	42.73	46.94
	Earnings	(0.46)	1.06	8.24	4.58	10.44	9.09	12.97	14.05	(2.08)	15.46
	Cash flow	0.96	3.40	5.00	6.11	12.52	10.26	16.13	13.73	(1.91)	14.20
	Capex	(0.23)	(0.40)	(0.38)	(0.29)	(1.00)	(0.91)	(0.80)	(1.00)	(1.88)	(1.71)
	Free cash flow	0.73	3.00	4.62	5.82	11.52	9.35	15.33	12.72	(3.79)	12.49
	Book value	5.47	8.21	17.44	23.71	33.44	39.19	54.33	68.22	63.63	73.00
	Shares, m	245	249	254	257	260	258	256	258	258	256
Valuation, ×
Valuation, ×	P/E	0.00	142.91	20.11	47.91	22.68	24.13	22.04	29.27	0.00	29.31
	P/S	10.77	15.29	13.83	13.50	9.89	7.47	8.20	10.73	9.42	9.66
	P/B	13.69	18.63	9.50	9.24	7.07	5.60	5.27	6.02	6.33	6.21
	EV/Sales	10.38	14.81	13.08	12.79	8.96	6.58	7.08	9.66	8.91	9.14
	EV/FCF	98.38	49.43	33.92	35.63	18.57	20.71	16.10	28.57	(100.36)	34.36
Cash, $m
Cash, $m	Operating cash flow	236	845	1,270	1,569	3,254	2,644	4,130	3,537	(493)	3,631
	Capex	(57)	(99)	(95)	(75)	(260)	(235)	(205)	(258)	(485)	(438)
	Free cash flow	180	746	1,175	1,494	2,994	2,409	3,925	3,279	(978)	3,194
Balance, $m
Balance, $m	Working capital	1,039	1,842	2,723	3,488	6,256	7,419	10,493	10,597	6,032	7,340
	Total debt	821	584	582	539	539	510	431	376	113	—
	Net debt	(661)	(1,505)	(2,587)	(3,270)	(6,120)	(7,015)	(10,348)	(10,842)	(6,003)	(6,608)
	Shareholders’ equity	1,338	2,042	4,435	6,085	8,687	10,100	13,913	17,580	16,410	18,666
Returns, %
Returns, %	ROA	(4.15)	8.18	42.83	16.16	27.02	18.60	21.04	17.71	(2.37)	16.41
	ROIC	0.92	14.33	21.48	26.58	69.55	56.37	75.52	35.54	(1.40)	21.63
	ROE	(9.22)	15.59	64.74	22.37	36.71	24.93	27.67	22.99	(3.15)	22.54

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VRTX Vertex Pharmaceuticals Incorporated	$129.0B	28.8×	25.5×	+12.45% (above 0%: growing)	+7.96% (above 0%: growing)	+9.25% (above 0%: growing)	85.33%	37.40%
MRNA Moderna, Inc.	$94.4B	— (loss-making)	— (loss-making)	+2.11% (above 0%: growing)	n/m	+38.94% (above 0%: growing)	35.86%	(562.07%)	Compare
REGN Regeneron Pharmaceuticals, Inc.	$82.0B	18.9×	16.5×	+16.73% (above 0%: growing)	−4.68% (below 0%: shrinking)	−29.26% (below 0%: shrinking)	86.56%	30.15%	Compare
ARGX argenex SE	$53.2B	29.6×	32.4×	+59.46% (above 0%: growing)	+88.56% (above 0%: growing)	+537.51% (above 0%: growing)	90.60%	32.04%	Compare
RVMD Revolution Medicines, Inc.	$40.6B	— (loss-making)	— (loss-making)	−77.89% (below 0%: shrinking)	n/m	−69.98% (below 0%: shrinking)	100.00%	0.00%	Compare
ONC BeOne Medicines Ltd. - Sponsored ADR	$39.0B	62.6×	40.2×	+29.63% (above 0%: growing)	+143.68% (above 0%: growing)	+117.92% (above 0%: growing)	89.76%	19.06%	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
Median of peers	$39.8B	39.5×	32.4×	+16.62%	+41.94%	+35.26%	88.16%	18.50%

All 614 Biotechnology stocks →

Vertex Pharmaceuticals Incorporated (VRTX) key facts

Strength: Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
Vertex Pharmaceuticals Incorporated (VRTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Net income was $4.0 billion, or $15.46 per share (basic), a net margin of 32.9%.
As of October 16, 2026, VRTX traded at $499.39, a market capitalization of $129.0 billion.
At that price the stock trades at 28.8× trailing-twelve-month earnings and 10.1× sales; its P/E is higher than 57% of its own readings over the past ten years.
Return on equity was 22.5% and debt-to-equity 0.00.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 12.06 (safe zone) for fiscal 2025.